PARP1 and chondrosarcoma: Thus, although the monotherapy dose was still higher than in clinically observed plasma concentrations (approximately 26 to 55 nM [14, 41]), the observed sensitivity for PARP inhibition in 2D and 3D chondrosarcoma cultures would support further exploration of PARP inhibition for patients with chondrosarcoma.